Axsome Therapeutics Inc (AXSM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Axsome Therapeutics Inc   (NASDAQ: AXSM)


Axsome Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Axsome Therapeutics Inc's ROI in the second quarter of 2026?
Axsome Therapeutics Inc recorded a cumulative net loss of $-192 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -64.13%.

Within the Healthcare sector 128 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3743 to 3744.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -5.26 % -10.08 % -7.58 % -12.64 % -25.73 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 301 274 311 309 298
Return On Investment (TTM) -64.13 % -63.19 % -57.68 % -70.74 % -78.27 %
AXSM's Overall Ranking # 3744 # 3743 # 3424 # 1629 # 3509
Seq. Investment Change TTM 0.28 % -6.17 % -2.11 % 2.86 % -4.83 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -192 -188 -183 -230 -247

AXSM Company Profile >> Back to AXSM Roi Comparisons >> See Annual AXSM Return On Investment



Return On Investment AXSM's Ranking
Within: No.
Industry # 42
Sector # 129
Overall # 3744

Return On Investment Statistics
High Average Low
-18.45 %
-98.47 %
-324.41 %
(Mar 31 2018)   (Dec 31 2018)



  News about Axsome Therapeutics Inc Return on Investment ROI

Axsome Therapeutics Advances AXS-07 A New Hope for Migraine Sufferers with FDA NDA Resubmission Acceptance

September 4, 2024

In a significant leap forward in the quest for effective migraine treatments, Axsome Therapeutics has announced the FDA s acceptance of their New Drug Application (NDA) resubmission for AXS-07, a promising candidate for the acute treatment of migraine. With the decision paving the way for review, all eyes are on the January 31, 2025 PDUFA (Prescription Drug User Fee Act) action goal date, a moment that could redefine therapeutic options for the millions suffering from debilitating migraines.Migraine, a condition affecting nearly 39 million individuals in the United States alone, is characterized by severe headache often accompanied by nausea and sensitivity to light and sound. Current treatment options remain limited, and many patients continue to endure inadequately managed symptoms, underscoring the urgent need for innovative therapies. AXS-07 an investigational medicine that combines two established drugs, meloxicam and rizatriptan has the potential to provide quick relief and improved outcomes for patients.

Axsome Therapeutics Generates Strong Net Revenue in Q4 2023, But Cumulative Net Loss Signals Concerns Over Financial Performance

January 4, 2024


The preliminary financial report reveals that Axsome Therapeutics generated $71 million in net product revenue during the fourth quarter of 2023, while the net revenue for the full year amounted to $204 million. Although these numbers show a significant increase in sales and a growing market presence, they must be analyzed in the context of the company s considerable net loss of $-202 million during the 12-month period ending in the third quarter of 2023. This cumulative loss resulted in a negative return on investment (ROI) of -53.6%.
The negative ROI figure raises concerns about Axsome Therapeutics ability to effectively manage its financial performance and generate profitable growth. Within the healthcare sector alone, the company lags behind 464 other companies with higher ROI figures, suggesting underlying operational or strategic issues. The consistent net loss over the reporting period has likely eroded investor confidence and may pose challenges for attracting new funding or partnership opportunities.





Financial Statements
Axsome Therapeutics Inc's II. Quarter Investments $ 301 Millions AXSM's Balance sheet
Axsome Therapeutics Inc's II. Quarter Income $ -51 Millions Quarterly AXSM's Income Statement
AXSM's Income by Division See AXSM's Income by Division


AXSM Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 311 338 449 235 65
Y / Y Investment Growth -8.1 % -24.7 % 91.3 % 262.97 % -60.22 %
Net Income in Millions -183 -287 -239 -187 -130
Y / Y Net Income Growth - - - - -
Annual Return On Investment -58.9 % -84.88 % -53.24 % -79.66 % -201.49 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AXSM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AXSM's Competitors
Subscribers only: Roi for Axsome Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for AXSM's Customers

Other Ratios
AXSM's Roa AXSM's Inventory Turnover Ratio AXSM's Growth Rates AXSM's Dividend Statistics
AXSM's Profitability Ratios AXSM's Asset Turnover Ratio AXSM's Dividend Growth
AXSM's Roe AXSM's Valuation Ratios AXSM's Financial Strength Ratios AXSM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:22:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.